Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Geoffrey Liu, MD"'
Autor:
William Tompkins, MD, Connor B. Grady, MPH, Wei-Ting Hwang, PhD, Krishna Chandrasekhara, Caroline McCoach, MD, Fangdi Sun, MD, Geoffrey Liu, MD, Devalben Patel, MD, Jorge Nieva, MD, Amanda Herrmann, MD, Kristen Marrone, MD, Vincent K. Lam, MD, Vamsi Velcheti, MD, Stephen V. Liu, MD, Gabriela Liliana Bravo Montenegro, MD, Tejas Patil, MD, Jared Weiss, MD, Kelsey Leigh Miller, MD, William Schwartzman, MD, Jonathan E. Dowell, MD, Khvaramze Shaverdashvili, MD, Liza Villaruz, MD, Amanda Cass, PharmD, Wade Iams, MD, Dara Aisner, MD, PhD, Charu Aggarwal, MD, D. Ross Camidge, MD, PhD, Melina E. Marmarelis, MD, Lova Sun, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 8, Pp 100669- (2024)
Introduction: Characteristics of long-term survivors in EGFR-mutant (EGFRm) NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to
Externí odkaz:
https://doaj.org/article/0d3a7a8c7ded4bf788294fa0471d93f0
Autor:
Kaitlin H. Chen, BSc, Tristan A. Barnes, MD, BS, Janessa Laskin, MD, Parneet Cheema, MD, MBiotech, Geoffrey Liu, MD, MS, Mussawar Iqbal, MD, Jeffrey Rothenstein, MD, Ronald Burkes, MD, Ming-Sound Tsao, MD, Natasha B. Leighl, MD, MMSc
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 1, Pp 100615- (2024)
Introduction: Liquid biopsy is recommended to diagnose molecular resistance to targeted therapy in patients with lung cancer. Nevertheless, not all jurisdictions provide funding and patient access. We report patients’ perceived value of liquid biop
Externí odkaz:
https://doaj.org/article/bb83005dd58b4c3492bec95a48fdc8a9
Autor:
Sally C.M. Lau, MD, MPH, Kirstin Perdrizet, MD, Andrea S. Fung, MD, PhD, Danilo Giffoni M.M. Mata, MD, Jessica Weiss, PhD, Nick Holzapfel, MD, Geoffrey Liu, MD, Penelope A. Bradbury, MD, Frances A. Shepherd, MD, Adrian G. Sacher, MD, MMSc, Harriet Feilotter, MD, Brandon Sheffield, MD, David Hwang, MD, Ming Sound Tsao, MD, Susanna Cheng, MD, Parneet Cheema, MD, Natasha B. Leighl, MD, MMSc
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100562- (2023)
Introduction: NSCLC with MET exon 14 skipping mutation (METex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore, sought to characterize the treatm
Externí odkaz:
https://doaj.org/article/1c185004b807431a8e7cb5c371cc5890
Autor:
Marie-Pier Gauthier, MD, Jennifer H. Law, MSc, Lisa W. Le, MSc, Janice J.N. Li, BSc, Sajda Zahir, Sharon Nirmalakumar, BSc, Mike Sung, MD, Christopher Pettengell, BMBCh, Steven Aviv, BBusSc, Ryan Chu, MD, Adrian Sacher, MD, MSc, Geoffrey Liu, MD, MSc, Penelope Bradbury, MBChB, Frances A. Shepherd, MD, Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100340- (2022)
Introduction: Real-world evidence is important in regulatory and funding decisions. Manual data extraction from electronic health records (EHRs) is time-consuming and challenging to maintain. Automated extraction using natural language processing (NL
Externí odkaz:
https://doaj.org/article/2e86472fb96d485497868949b557bcaa
Autor:
Mike R. Sung, MD, Pascale Tomasini, MD, Lisa W. Le, MSc, Suzanne Kamel-Reid, MD, Ming-Sound Tsao, MD, Geoffrey Liu, MD, Penelope A. Bradbury, MD, Frances A. Shepherd, MD, Janice J.N. Li, BSc, Ronald Feld, MD, Natasha B. Leighl, MD, MMSc, FRCPC
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100259- (2022)
Introduction: In addition to the higher prevalence of EGFR mutations found among lung cancer cases in East Asian patients, it is unclear whether there are differences in treatment outcomes by ethnicity—that is, East Asian versus non–East Asian. M
Externí odkaz:
https://doaj.org/article/e0eb9e70ba5e4d6cabf8c27d1a19aa6f
Autor:
Sally C.M. Lau, MD, MPH, Malcolm Ryan, BSc, Jessica Weiss, PhD, Aline Fusco Fares, MD, Miguel Garcia, MD, Sabine Schmid, MD, Shelley Kuang, MD, Deirdre Kelly, MB BCh BAO, Ming Sound Tsao, MD, Penelope A. Bradbury, MB BCh, Byoung Chun J. Cho, MD, Alexander Sun, MD, Srinivas Raman, MD, Andrew Hope, MD, Meredith Giuliani, MBBS, MEd, PhD, Benjamin H. Lok, MD, PhD, Andrea Bezjak, MD, Geoffrey Liu, MD, MSc, Natasha B. Leighl, MD, MSc, Frances A. Shepherd, MD, Adrian G. Sacher, MD, MMSc
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 12, Pp 100251- (2021)
Introduction: The addition of durvalumab after chemoradiation therapy (CRT) in unresectable stage III NSCLC significantly improves survival. The benefit of this approach in elderly patients is controversial given the toxicity associated with CRT and,
Externí odkaz:
https://doaj.org/article/eafc28dbd2bc49cd99b777e1bd11e394
Autor:
Stewart DJ; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Ramsay T; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Navani V; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Liu G; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Jiang DM; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada., Batist G; David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Mar 10; Vol. 42 (8), pp. 973-974. Date of Electronic Publication: 2024 Jan 30.